

Daniel A Rodrigues

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1388544/publications.pdf>

Version: 2024-02-01

21
papers

872
citations

687363

13
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

1675
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in the Design and Development of PROTAC-mediated HDAC Degradation. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 408-424.	2.1	10
2	Recent Advances in the Use of Multitarget Therapeutics. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 331-332.	2.1	0
3	Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol 3-kinase (PI3K): Current and Future Prospects. <i>ChemMedChem</i> , 2021, 16, 448-457.	3.2	16
4	Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer. <i>Pharmaceuticals</i> , 2021, 14, 387.	3.8	8
5	Structure–property relationship studies of 3-acyl-substituted furans: the serendipitous identification and characterization of a new non-classical hydrogen bond donor moiety. <i>New Journal of Chemistry</i> , 2020, 44, 10994-11005.	2.8	3
6	Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. <i>Medicinal Research Reviews</i> , 2020, 40, 2177-2211.	10.5	38
7	Design, Synthesis, and Pharmacological Evaluation of First-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3K Inhibitors. <i>ChemMedChem</i> , 2020, 15, 539-551.	3.2	28
8	Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. <i>Pharmaceuticals</i> , 2019, 12, 69.	3.8	53
9	The Use of Conformational Restriction in Medicinal Chemistry. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1712-1733.	2.1	26
10	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5805-5821.	6.4	343
11	Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPR40). <i>Chemical Biology and Drug Design</i> , 2018, 91, 668-680.	3.2	11
12	Theoretical and experimental characterization of 1,4-N-H...S...hole intramolecular interactions in bioactive N-acylhydrazone derivatives. <i>New Journal of Chemistry</i> , 2018, 42, 497-505.	2.8	15
13	Modeling zinc–oxygen coordination in histone deacetylase: A comparison of semiempirical methods performance. <i>International Journal of Quantum Chemistry</i> , 2018, 118, e25720.	2.0	5
14	N-Acylhydrazones as drugs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2797-2806.	2.2	140
15	An Unusual Intramolecular Halogen Bond Guides Conformational Selection. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 9970-9975.	13.8	12
16	Recent Advances in Development of Polyphenols as Anticancer Agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2018, 18, 1265-1269.	2.4	13
17	Design, synthesis, structural characterization and in vitro cytotoxic activity of mononuclear Ru(II) complexes. <i>Medicinal Chemistry Research</i> , 2016, 25, 2127-2132.	2.4	1
18	Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 655-670.	6.4	86

#	ARTICLE	IF	CITATIONS
19	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. <i>International Journal of Biological Macromolecules</i> , 2016, 82, 663-670.	7.5	33
20	Beyond the Selective Inhibition of Histone Deacetylase 6. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 16, 1175-1184.	2.4	17
21	Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 214-221.	5.5	14